Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy
Shunying Li(Sun Yat-sen University), Qiang Liu(Sun Yat-sen University), Yaping Yang(Sun Yat-sen University), Chang Gong(Sun Yat-sen University), Wei Wu(Moderna Therapeutics (United States)), Yan Nie(Fourth Affiliated Hospital of China Medical University), Wei Wei, Yuhua Gong, Yudong Li(Zhengzhou University), Ting Wang(Jilin University), Jun Zhang(Shenzhen University Health Science Center), Fang Li(Hebei General Hospital), Xin Yi, Fengyan Yu(Sun Yat-sen University), Xingrui Li(Huazhong University of Science and Technology), Huawei Yang(Ludong University), Yan Xu(Daping Hospital), Guangxin Li(Yale University), Liang Jin(Kunming Medical University), Feng Yao(Wuhan University), Jianghua Ou(Xinjiang Medical University), Nanyan Rao(Sun Yat-sen University), Weijuan Jia(Sun Yat-sen University), Mengzi Wu(Jiangsu University)
Cited by 23
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
|Nature Communications|2019|434
Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
|Cell Metabolism|2018|420
Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis
|Nature Metabolism|2019|351